Vorinostat and romidepsin are Food and Drug Administration-approved HDAC inhibitors for treatment of T-cell lymphoma (Giannini et al., 2012; Khan and La Thangue, 2012). This evidence concerns the gene HDAC9 and T-cell non-Hodgkin lymphoma.